The last 10 global press releases

To find more press releases: 

2022
2021
2020
2019
2018
2017
2016
February 3, 2023
Press releases
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
January 30, 2023
Press releases
Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
January 27, 2023
Press releases
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
January 25, 2023
Press releases
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
January 11, 2023
Press releases
Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
January 5, 2023
Press releases
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
January 4, 2023
Press releases
Press Release: Availability of the Q4 2022 Memorandum for modelling purposes
December 21, 2022
Press releases
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
December 19, 2022
Press releases
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
December 16, 2022
Press releases
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis

Local press releases

September 3, 2020 - US
Late-breaking Libtayo® (cemiplimab) pivotal data in advanced non-small cell lung cancer and basal cell carcinoma to be presented at ESMO

September 9, 2020 - US
Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020